Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Granxinning after PCI in coronary microvascular dysfunction
ChiCTR2300074239Phase 4Recruiting
- Sponsor
- Shanxi Provincial People's Hospital
- Start
- Jan 2023
- Countries
- 1
01
Overview
Phase 4, randomised trial of Guanxinning in coronary arteriosclerosis and Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Shanxi Provincial People's Hospital. Primary endpoints: Seattle Chest Pain Scale, Inflammatory biomarkers (SIRT1, NLRP3, IL-18, LECT2, Irisin, sST2, TNFRSF18 and others) and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
Guanxinning
03
Conditions
coronary arteriosclerosisCoronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR2300074239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074239.